ReviewNature biomedical engineering2018
Harnessing cell pluripotency for cardiovascular regenerative medicine.
Review in Nature biomedical engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Engineered LINC MIR503HG-loaded extracellular vesicles maintain stemness and pluripotency during long-term hiPSCs culture.Bioactive materials · 2026Article
- Oxygen Handling Practices for in Vitro Human Pluripotent Stem Cell Cardiomyocyte Differentiation: A Scoping Literature Review.Stem cell reviews and reports · 2026Article
- Generation of two induced pluripotent stem cell lines to model and investigate diseases affecting Pacific Islanders.Stem cell research · 2025Article
- Current Review of Regenerative Medicine Therapies for Spine-Related Pain.Current pain and headache reports · 2024Review
- Combining Cell Technologies With Biomimetic Tissue Engineering Applications: A New Paradigm for Translational Cardiovascular Therapies.Stem cells translational medicine · 2023Review
- Comparative analysis of the cardiomyocyte differentiation potential of induced pluripotent stem cells reprogrammed from human atrial or ventricular fibroblasts.Frontiers in bioengineering and biotechnology · 2023Article
- Translational perspectives on cardiac reprogramming.Seminars in cell & developmental biology · 2022Review
- Emerging nanotechnologies in cardiovascular medicine.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Organ-on-a-chip systems for vascular biology.Journal of molecular and cellular cardiology · 2021Review
- Cellular and molecular landscape of mammalian sinoatrial node revealed by single-cell RNA sequencing.Nature communications · 2021Article
- 4D physiologically adaptable cardiac patch: A 4-month in vivo study for the treatment of myocardial infarction.Science advances · 2020Article
- Signaling pathways in modulation of tissue and organ regeneration in vertebrates.Seminars in cell & developmental biology · 2020Article
- Heart regeneration with human pluripotent stem cells: Prospects and challenges.Bioactive materials · 2020Review
- Recent Development in Therapeutic Cardiac Patches.Frontiers in cardiovascular medicine · 2020Review
- Intensive care for human hearts in pluripotent stem cell models.NPJ Regenerative medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Human pluripotent stem cells (hPSCs), in particular embryonic stem cells and induced pluripotent stem cells, have received enormous attention in cardiovascular regenerative medicine owing to their ability to expand and differentiate into functional cardiomyocytes and other cardiovascular cell types. Despite the potential applications of hPSCs for tissue regeneration in patients suffering from cardiovascular disease, whether hPSC-based therapies can be safe and efficacious remains inconclusive, with strong evidence from clinical trials lacking. Critical factors limiting therapeutic efficacy are the degree of maturity and purity of the hPSC-derived differentiated progeny, and the tumorigenic risk associated with residual undifferentiated cells. In this Review, we discuss recent advances in cardiac-cell differentiation from hPSCs and in the direct reprogramming of non-myocyte cells for cardiovascular regenerative applications. We also discuss approaches for the delivery of cells to diseased tissue, and how such advances are contributing to progress in cardiac tissue engineering for tackling heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.